successful LN excision without complication. The mean time interval between WFL and surgery was 162 days (range 4-270, median 191 days). A single supplementary wire was performed for surgeon’s learning curve. No obscuring artifact was noted in 25 MRI exams
Search Results
Mary K. Hayes, Mayra Frau, Erica Bloomquist, and Heather Wright
Dadasaheb Akolkar, Darshana Patil, Anantbhushan Ranade, Revati Patil, Sachin Apurwa, Sanket Patil, Pradip Fulmali, Pradip Devhare, Navin Srivastava, Ajay Srinivasan, and Rajan Datar
integrated to generate patient-specific therapy recommendations. All patients underwent whole body PET-CT and brain MRI scans prior to start of treatment. Treatment response was determined from follow-up PET-CT scans and used to calculate Objective Response
Therese B. Bevers, Benjamin O. Anderson, Ermelinda Bonaccio, Sandra Buys, Mary B. Daly, Peter J. Dempsey, William B. Farrar, Irving Fleming, Judy E. Garber, Randall E. Harris, Alexandra S. Heerdt, Mark Helvie, John G. Huff, Nazanin Khakpour, Seema A. Khan, Helen Krontiras, Gary Lyman, Elizabeth Rafferty, Sara Shaw, Mary Lou Smith, Theodore N. Tsangaris, Cheryl Williams, and Thomas Yankeelov
with her breasts), physical examination, risk assessment, screening mammography, and, in selected cases, screening MRI. A diagnostic breast evaluation differs from breast screening in that it is used to evaluate an existing problem (e.g., dominant
Presenter: Jens Hillengass
, serum free light chains, flow cytometry, immunoparesis, MRI, and fluorescence in situ hybridization (FISH). Clinicians should also consider the concept of evolving smoldering MM, said Dr. Hillengass, because dynamically stable markers of disease are
Peter H. Carroll and James L. Mohler
MRI. Further, they support the use of active surveillance in men identified to have low-risk cancers, linked to and compliant with the NCCN Guidelines for Prostate Cancer. Dr. Carroll acknowledged that in the 1990s and 2000s, routine screening was
L. Burt Nabors
combinations in the setting of recurrent disease. We would alert the oncology community to a couple of unique aspects concerning the use of bevacizumab in GBM. First, bevacizumab has an impact on diagnostic imaging studies, particularly MRI. A misconception
examinations, MRI evaluations, and serum biomarker assessments. All patients will be treated until radiographic or clinical evidence is seen of disease progression or unacceptable toxicity. Patients may withdraw from the study at any time. Primary Objective
Stephen B. Edge
address in controlled clinical trials. Technological Advances and Controversies A major change in breast surgery practice has been the use of MRI. Compared with other breast imaging, breast MRI may provide better information on the extent of a
Benjamin L. Franc, Timothy P. Copeland, Robert Thombley, Miran Park, Ben Marafino, Mitzi L. Dean, W. John Boscardin, Hope S. Rugo, David Seidenwurm, Bhupinder Sharma, Stephen R. Johnston, and R. Adams Dudley
breast cancer diagnosed by age 50 years, receive dedicated breast MRI annually. 2 ASCO and NCCN have issued guidelines stating that, after initial treatment, surveillance for recurrence in patients with stage I–III breast cancer should include periodic
Bethany L. Niell
with a breast biopsy in 2010 through 2012. Claims for high-cost imaging studies, such as CT, brain or body MRI, PET, and bone scans, in the 18-month postoperative period were included if the imaging was performed for a breast cancer indication. The
